How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer

May 18, 2023

Article

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

Chris Spivey, editorial director, speaks with Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer. In this interview, True shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry, including changes to the "just-in-time" supply chain, pandemic preparedness, and more.

Related Content

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol

November 21st 2024

Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

June 25th 2024

Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol

November 20th 2024

Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Frontier Scientific Solutions Plans a Global Free Trade Zone Gateway to Supply Life Sciences Industry on Back of $1.5 Billion Investment

Feliza Mirasol

November 16th 2024

Article

Frontier Scientific Solutions has unveiled plans to use a $1.5 billion commitment from a major investor to create a global free trade zone gateway to facilitate the life sciences supply chain using Wilmington International Airport in North Carolina.